Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Odar

Cardiovascular Disease Rockville, MD Medical Doctor

NPI 1457387458 CMS profile 111758

15225 Shady Grove Rd, Suite 201, Rockville, MD 20850

Open in the dashboard

General payments

$6,053

320 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Odar of Rockville, MD is reported in the CMS Open Payments database as having received $6,053 across 320 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,187 60
2024 General $970 45
2023 General $809 45
2022 General $818 41
2021 General $1,029 67
2020 General $544 29
2019 General $697 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Odar
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Thomas Odar were reported at $1,187. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Thomas Odar Cardiovascular Disease median Middle half National median
2019 $697 $450 $127–$1,392 $163
2020 $544 $242 $77–$751 $114
2021 $1,029 $335 $101–$1,037 $132
2022 $818 $395 $121–$1,211 $149
2023 $809 $443 $136–$1,283 $160
2024 $970 $450 $136–$1,323 $164
2025 $1,187 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amarin Pharma Inc. $597 28 payments
  2. Amgen Inc. $545 29 payments
  3. Merck Sharp & Dohme Corporation $500 28 payments
  4. Janssen Pharmaceuticals, Inc $435 29 payments
  5. Pfizer Inc. $419 25 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $413 21 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $380 23 payments
  8. E.R. Squibb & Sons, L.L.C. $363 21 payments
  9. Novartis Pharmaceuticals Corporation $295 12 payments
  10. Atricure, Inc. $250 8 payments
  11. Other $1,855 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,039 319 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Vascepa $597 28 payments
  2. VERQUVO $553 31 payments
  3. XARELTO $435 29 payments
  4. Repatha $434 25 payments
  5. LifeVest $380 23 payments
  6. ELIQUIS $291 18 payments
  7. JARDIANCE Diabetes $229 12 payments
  8. FUROSCIX $194 9 payments
  9. JARDIANCE Diabetes $184 9 payments
  10. CAMZYOS $182 11 payments
  11. Other $3,175 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

3,502

Median for Cardiology: 2,533

Drug cost

$673,314

Median for Cardiology: $485,213

Branded share of claims

20.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 265 $358,959
Entresto Sacubitril/Valsartan Brand 43 $70,911
Xarelto Rivaroxaban Brand 37 $59,472
Praluent Pen Alirocumab Brand 22 $27,141
Repatha Sureclick Evolocumab Brand 16 $23,626
Nexletol Bempedoic Acid Brand 32 $20,607
Farxiga Dapagliflozin Propanediol Brand 14 $18,561
Nexlizet Bempedoic Acid/Ezetimibe Brand 13 $14,844
Brilinta Ticagrelor Brand 15 $12,905
Metoprolol Succinate Generic 445 $8,215

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$466,613

Of which drugs: $2,592

Medicare patients

1,686

Average age 76

Services billed

5,601

852 women, 834 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 49%
Arthritis 46%
Diabetes 38%
Atrial fibrillation 30%
Chronic kidney disease 28%
Heart failure 25%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 124 486 $2,592

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $140
$140 16 —
ELIQUIS
  • PFIZER INC. $74
  • E.R. Squibb & Sons, L.L.C. $61
$135 265 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $57
$57 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $53
$53 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record